Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
Jingran Ji1, Chongkai Wang1, Marwan Fakih1
1Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Abstract:
Identifying mutations in the KRAS gene has become increasingly important in the treatment of colorectal cancer with many prognostic and therapeutic implications. However, efforts to develop drugs that target KRAS mutations have not been successful until more recently with the introduction of the KRAS G12C inhibitors, sotorasib (AMG510) and adagrasib (MRTX849). Both agents have demonstrated safety and promising efficacy in preclinical studies and early phase trials, but it appears that not all tumor types harboring the KRAS G12C mutation are sensitive to monotherapy approaches. In particular, patients with colorectal cancer (CRC) derive less benefit compared to those with non-small cell lung cancer (NSCLC), likely due to rapid treatment-induced resistance through increased epidermal growth factor receptor (EGFR) signaling. As a result, combination therapy trials with EGFR inhibitors are currently underway. Here, we will review the available clinical trial data on KRASG12C inhibitors in KRAS G12C-mutated CRC, possible mechanisms of resistance to monotherapy, the research studying why available agents are proving to be less efficacious in CRC compared to NSCLC, and future directions for these promising new drugs.
Insights
New KRAS G12C inhibitors show promise for colorectal cancer (CRC) treatment. Combination therapies targeting resistance mechanisms are being explored to improve efficacy in CRC patients compared to non-small cell lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS gene mutations are critical in colorectal cancer (CRC) prognosis and treatment.
- KRAS G12C inhibitors, sotorasib and adagrasib, represent recent therapeutic advancements.
- Monotherapy with KRAS G12C inhibitors shows variable efficacy across tumor types.
Purpose of the Study:
- To review clinical trial data for KRAS G12C inhibitors in KRAS G12C-mutated CRC.
- To explore mechanisms of resistance to KRAS G12C inhibitor monotherapy.
- To investigate differential efficacy between CRC and non-small cell lung cancer (NSCLC).
Main Methods:
- Review of preclinical studies and early-phase clinical trial data.
- Analysis of resistance mechanisms, including EGFR signaling.
- Comparative analysis of treatment outcomes in CRC versus NSCLC.
Main Results:
- KRAS G12C inhibitors demonstrate safety and efficacy in initial studies.
- Colorectal cancer patients show less benefit from monotherapy compared to NSCLC patients.
- Increased epidermal growth factor receptor (EGFR) signaling is a potential resistance mechanism in CRC.
Conclusions:
- Combination therapy trials with EGFR inhibitors are warranted for KRAS G12C-mutated CRC.
- Understanding resistance mechanisms is crucial for optimizing KRAS G12C inhibitor therapy.
- Further research is needed to enhance the efficacy of these agents in colorectal cancer.
More Related Videos
06:19Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
Published on: July 18, 2017
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...